Glucocorticoids limit acute lung inflammation in concert with inflammatory stimuli by induction of SphK1

Nature Communications

Volumn 6, Issue , 2015, Pages

  Vettorazzi, Sabine ^a,b   Bode, Constantin ^c   Dejager, Lien ^d   Frappart, Lucien ^e   Shelest, Ekaterina ^f   Klaßen, Carina ^g   Tasdogan, Alpaslan ^a   Reichardt, Holger M ^g   Libert, Claude ^d   Schneider, Marion ^h   Weih, Falk ^b   Uhlenhaut, N Henriette ⁱ   David, Jean Pierre ^j   Gräler, Markus ^c,k   Kleiman, Anna ^b,k   Tuckermann, Jan P ^a,b  

^a UNIVERSITY OF ULM   (Germany)

^b FRITZ LIPMANN INSTITUTE   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d GHENT UNIVERSITY   (Belgium)

^e EDOUARD HERRIOT HOSPITAL   (France)

^f HANS KNÖLL INSTITUTE   (Germany)

^g UNIVERSITY OF GÖTTINGEN   (Germany)

^h UNIVERSITY HOSPITAL ULM   (Germany)

ⁱ INSTITUTE OF EPIDEMIOLOGY   (Germany)

^j UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^k JENA UNIVERSITY HOSPITAL   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE 1; STRESS ACTIVATED PROTEIN KINASE 1; CYTOKINE; GLUCOCORTICOID; LYSOPHOSPHOLIPID; MITOGEN AND STRESS-ACTIVATED PROTEIN KINASE 1; PHOSPHOTRANSFERASE; S6 KINASE; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE; SPHINGOSINE KINASE;

ABNORMALITY; CELLS AND CELL COMPONENTS; ENZYME ACTIVITY; IMMUNE RESPONSE; INHIBITION; PHOSPHATE; PROTEIN; STEROID;

ACUTE LUNG INJURY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE MARROW CELL; CELL INFILTRATION; CONTROLLED STUDY; DIMERIZATION; FEMALE; GENE EXPRESSION REGULATION; GENE INDUCTION; LUNG LAVAGE; MACROPHAGE; MACROPHAGE FUNCTION; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PNEUMONIA; PROTEIN EXPRESSION; THERAPY EFFECT; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; CHROMATIN IMMUNOPRECIPITATION; DRUG EFFECTS; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; INFLAMMATION; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION; UPREGULATION;

ACUTE LUNG INJURY; ANIMALS; CHROMATIN IMMUNOPRECIPITATION; CYTOKINES; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GLUCOCORTICOIDS; INFLAMMATION; LYSOPHOSPHOLIPIDS; MACROPHAGES; MICE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, GLUCOCORTICOID; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; SPHINGOSINE; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 84937468854     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms8796     Document Type: Article

References (70)

1. Ware, L. B. & Matthay, M. A. The acute respiratory distress syndrome. N. Engl. J. Med. 342, 1334-1349 (2000).
2. Bernard, G. R. et al. Report of the American-European Consensus conference on acute respiratory distress syndrome: definitions, mechanisms, relevant outcomes, and clinical trial coordination. Consensus Committee. J. Crit. Care. 9, 72-81 (1994).
3. Herridge, M. S. et al. One-year outcomes in survivors of the acute respiratory distress syndrome. N. Engl. J. Med. 348, 683-693 (2003).
4. Khilnani, G. C. & Hadda, V. Corticosteroids and ARDS: A review of treatment and prevention evidence. Lung India 28, 114-119 (2011).
5. Tang, B. M., Craig, J. C., Eslick, G. D., Seppelt, I. & McLean, A. S. Use of corticosteroids in acute lung injury and acute respiratory distress syndrome: a systematic review and meta-analysis. Crit. Care Med. 37, 1594-1603 (2009).
6. Marik, P. E., Meduri, G. U., Rocco, P. R. & Annane, D. Glucocorticoid treatment in acute lung injury and acute respiratory distress syndrome. Crit. Care Clin. 27, 589-607 (2011).
7. Meduri, G. U. et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest 131, 954-963 (2007).
8. Steinberg, K. P. et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N. Engl. J. Med. 354, 1671-1684 (2006).
9. Hubner, S. & Tuckermann, J. Molecular mechanisms of the glucocorticoid receptor in steroid therapy - lessons from transgenic mice. Biomol. Concepts 3, 241-253 (2012).
10. De Bosscher, K., Haegeman, G. & Elewaut, D. Targeting inflammation using selective glucocorticoid receptor modulators. Curr. Opin. Pharmacol. 10, 497-504 (2010).
11. Baschant, U. & Tuckermann, J. The role of the glucocorticoid receptor in inflammation and immunity. J. Steroid Biochem. Mol. Biol. 120, 69-75 (2010).
12. Frijters, R. et al. Prednisolone-induced differential gene expression in mouse liver carrying wild type or a dimerization-defective glucocorticoid receptor. BMC Genomics 11, 359 (2010).
13. Tuckermann, J. P. et al. Macrophages and neutrophils are the targets for immune suppression by glucocorticoids in contact allergy. J. Clin. Invest. 117, 1381-1390 (2007).
14. Baschant, U. et al. Glucocorticoid therapy of antigen-induced arthritis depends on the dimerized glucocorticoid receptor in T cells. Proc. Natl Acad. Sci. USA 108, 19317-19322 (2011).
15. Vandevyver, S. et al. Glucocorticoid receptor dimerization induces MKP1 to protect against TNF-induced inflammation. J. Clin. Invest. 122, 2130-2140 (2012).
16. Kleiman, A. et al. Glucocorticoid receptor dimerization is required for survival in septic shock via suppression of interleukin-1 in macrophages. FASEB J. 26, 722-729 (2012).
17. Bhattacharyya, S., Brown, D. E., Brewer, J. A., Vogt, S. K. & Muglia, L. J. Macrophage glucocorticoid receptors regulate Toll-like receptor 4-mediated inflammatory responses by selective inhibition of p38 MAP kinase. Blood 109, 4313-4319 (2007).
18. Patel, H. B. et al. The impact of endogenous annexin A1 on glucocorticoid control of inflammatory arthritis. Ann. Rheum. Dis. 71, 1872-1880 (2012).
19. Mehta, D. & Malik, A. B. Signaling mechanisms regulating endothelial permeability. Physiol. Rev. 86, 279-367 (2006).
20. Kohama, T. et al. Molecular cloning and functional characterization of murine sphingosine kinase. J. Biol. Chem. 273, 23722-23728 (1998).
21. Garcia, J. G. et al. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. J. Clin. Invest. 108, 689-701 (2001).
22. Camerer, E. et al. Sphingosine-1-phosphate in the plasma compartment regulates basal and inflammation-induced vascular leak in mice. J. Clin. Invest. 119, 1871-1879 (2009).
23. McVerry, B. J. et al. Sphingosine 1-phosphate reduces vascular leak in murine and canine models of acute lung injury. Am. J. Respir. Crit. Care Med. 170, 987-993 (2004).
24. Peng, X. et al. Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. Am. J. Respir. Crit. Care Med. 169, 1245-1251 (2004).
25. Tauseef, M. et al. Activation of sphingosine kinase-1 reverses the increase in lung vascular permeability through sphingosine-1-phosphate receptor signaling in endothelial cells. Circ. Res. 103, 1164-1172 (2008).
26. Bursten, S. L. et al. An increase in serum C18 unsaturated free fatty acids as a predictor of the development of acute respiratory distress syndrome. Crit. Care Med. 24, 1129-1136 (1996).
27. Quinlan, G. J., Lamb, N. J., Evans, T. W. & Gutteridge, J. M. Plasma fatty acid changes and increased lipid peroxidation in patients with adult respiratory distress syndrome. Crit. Care Med. 24, 241-246 (1996).
28. Matute-Bello, G. et al. An official American Thoracic Society workshop report: features and measurements of experimental acute lung injury in animals. Am. J. Respir. Cell Mol. Biol. 44, 725-738 (2011).
29. Matute-Bello, G., Frevert, C. W. & Martin, T. R. Animal models of acute lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 295, L379-L399 (2008).
30. Schuster, D. P. ARDS: clinical lessons from the oleic acid model of acute lung injury. Am. J. Respir. Crit. Care. Med. 149, 245-260 (1994).
31. Annane, D. Corticosteroids for severe sepsis: an evidence-based guide for physicians. Ann. Intensive Care 1, 7 (2011).
32. Matute-Bello, G. et al. Fas (CD95) induces alveolar epithelial cell apoptosis in vivo: implications for acute pulmonary inflammation. Am. J. Pathol. 158, 153-161 (2001).
33. Caton, M. L., Smith-Raska, M. R. & Reizis, B. Notch-RBP-J signaling controls the homeostasis of CD8-dendritic cells in the spleen. J. Exp. Med. 204, 1653-1664 (2007).
34. McVerry, B. J. & Garcia, J. G. In vitro and in vivo modulation of vascular barrier integrity by sphingosine 1-phosphate: mechanistic insights. Cell. Signal. 17, 131-139 (2005).
35. Boyle, A. J., Mac Sweeney, R. & McAuley, D. F. Pharmacological treatments in ARDS; a state-of-the-art update. BMC Med. 11, 166 (2013).
36. Zhao, Y. et al. Protection of LPS-induced murine acute lung injury by sphingosine-1-phosphate lyase suppression. Am. J. Respir. Cell Mol. Biol. 45, 426-435 (2011).
37. Ble, F. X. et al. Activation of the lung S1P(1) receptor reduces allergen-induced plasma leakage in mice. Br. J. Pharmacol. 158, 1295-1301 (2009).
38. Bode, C. et al. Erythrocytes serve as a reservoir for cellular and extracellular sphingosine 1-phosphate. J. Cell. Biochem. 109, 1232-1243 (2010).
39. Alvarez, S. E. et al. Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature 465, 1084-1088 (2010).
40. Nayak, D. et al. Sphingosine kinase 1 regulates the expression of proinflammatory cytokines and nitric oxide in activated microglia. Neuroscience 166, 132-144 (2010).
41. Wadgaonkar, R. et al. Differential regulation of sphingosine kinases 1 and 2 in lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 296, L603-L613 (2009).
42. Schaper, K. et al. Sphingosine-1-phosphate exhibits anti-proliferative and anti-inflammatory effects in mouse models of psoriasis. J. Dermatol. Sci. 71, 29-36 (2013).
43. Calabresi, P. A. et al. Safety and efficacy of fingolimod in patients with relapsingremitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 13, 545-556 (2014).
44. Chun, J. & Hartung, H. P. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin. Neuropharmacol. 33, 91-101 (2010).
45. Xiong, Y. et al. Sphingosine kinases are not required for inflammatory responses in macrophages. J. Biol. Chem. 288, 32563-32573 (2013).
46. Nakagawa, M. et al. Glucocorticoid-induced granulocytosis: contribution of marrow release and demargination of intravascular granulocytes. Circulation 98, 2307-2313 (1998).
47. Hammad, S. M. et al. Dual and distinct roles for sphingosine kinase 1 and sphingosine 1 phosphate in the response to inflammatory stimuli in RAW macrophages. Prostaglandins Other Lipid. Mediat. 85, 107-114 (2008).
48. Wu, W., Mosteller, R. D. & Broek, D. Sphingosine kinase protects lipopolysaccharide-activated macrophages from apoptosis. Mol. Cell. Biol. 24, 7359-7369 (2004).
49. Forster, A. et al. Glucocorticoids protect renal mesangial cells from apoptosis by increasing cellular sphingosine-1-phosphate. Kidney Int. 77, 870-879 (2010).
50. Nieuwenhuis, B. et al. Involvement of the ABC-transporter ABCC1 and the sphingosine 1-phosphate receptor subtype S1P(3) in the cytoprotection of human fibroblasts by the glucocorticoid dexamethasone. J. Mol. Med. 87, 645-657 (2009).
51. Lim, H. W. et al. Genomic redistribution of GR monomers and dimers mediates transcriptional response to exogenous glucocorticoid in vivo. Genome Res. 25, 836-844 (2015).
52. Shah, S., King, E. M., Chandrasekhar, A. & Newton, R. Roles for the mitogenactivated protein kinase (MAPK) phosphatase, DUSP1, in feedback control of inflammatory gene expression and repression by dexamethasone. J. Biol. Chem. 289, 13667-13679 (2014).
53. Roux, P. P. & Blenis, J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol. Mol. Biol. Rev. 68, 320-344 (2004).
54. Guma, M. et al. Antiinflammatory functions of p38 in mouse models of rheumatoid arthritis: advantages of targeting upstream kinases MKK-3 or MKK-6. Arthritis Rheum. 64, 2887-2895 (2012).
55. Arcaroli, J. et al. Role of p38 MAP kinase in the development of acute lung injury. Clin. Immunol. 101, 211-219 (2001).
56. Vermeulen, L., Vanden Berghe, W., Beck, I. M., De Bosscher, K. & Haegeman, G. The versatile role of MSKs in transcriptional regulation. Trends Biochem. Sci. 34, 311-318 (2009).
57. Sobue, S. et al. Implications of sphingosine kinase 1 expression level for the cellular sphingolipid rheostat: relevance as a marker for daunorubicin sensitivity of leukemia cells. Int. J. Hematol. 87, 266-275 (2008).
58. Beck, I. M. et al. Mitogen- and stress-activated protein kinase 1 MSK1 regulates glucocorticoid response element promoter activity in a glucocorticoid concentration-dependent manner. Eur. J. Pharmacol. 715, 1-9 (2013).
59. Beck, I. M. et al. Glucocorticoids and mitogen- and stress-activated protein kinase 1 inhibitors: possible partners in the combat against inflammation. Biochem. Pharmacol. 77, 1194-1205 (2009).
60. Garcia, J. G. Focusing on the flood: targeting functional polymorphisms in ALI permeability pathways. Am. J. Respir. Crit. Care Med. 183, 1287-1289 (2011).
61. Sun, X. et al. Functional promoter variants in sphingosine 1-phosphate receptor 3 associate with susceptibility to sepsis-associated acute respiratory distress syndrome. Am. J. Physiol. Lung Cell. Mol. Physiol. 305, L467-L477 (2013).
62. Reichardt, H. M. et al. DNA binding of the glucocorticoid receptor is not essential for survival. Cell 93, 531-541 (1998).
63. Böhm, C. et al. The alpha-isoform of p38 MAPK specifically regulates arthritic bone loss. J.I Immunol. 183, 5938-5947 (2009).
64. Engel, F. B. et al. p38 MAP kinase inhibition enables proliferation of adult mammalian cardiomyocytes. Genes Dev. 19, 1175-1187 (2005).
65. Zhou, Z., Kozlowski, J. & Schuster, D. P. Physiologic, biochemical, and imaging characterization of acute lung injury in mice. Am. J. Respir. Crit. Care Med. 172, 344-351 (2005).
66. Vlasenko, L. P. & Melendez, A. J. A critical role for sphingosine kinase in anaphylatoxin-induced neutropenia, peritonitis, and cytokine production in vivo. J. Immunol. 174, 6456-6461 (2005).
67. Sammani, S. et al. Differential effects of sphingosine 1-phosphate receptors on airway and vascular barrier function in the murine lung. Am. J. Respir. Cell Mol. Biol. 43, 394-402 (2010).
68. Bode, C. & Graler, M. H. Quantification of sphingosine-1-phosphate and related sphingolipids by liquid chromatography coupled to tandem mass spectrometry. Methods Mol. Biol. 874, 33-44 (2012).
69. Allende, M. L. et al. Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. J. Biol. Chem. 279, 52487-52492 (2004).
70. Uhlenhaut, N. H. et al. Insights into negative regulation by the glucocorticoid receptor from genome-wide profiling of inflammatory cistromes. Mol. Cell 49, 158-171 (2013).